|
Arecor offers partners the opportunity to validate the capabilities of Arestat™
to stabilize their proteins, vaccines or macromolecules against agreed in vitro
assays through a feasibility study. These studies typically take between 3-7 months
depending on the nature of the instability, the extent of analytical development
required and the type of the stability trials involved. The key deliverable of the
feasibility study is one or more candidate formulation(s) with required stability
data. This may be measured in terms of stability in the presence of industry-standard
level of ionizing radiation for sterilization and/or accelerated shelf storage trial
involving temperatures ranging from -20°C to +55°C. Upon completion of the feasibility
study Arecor can transfer the technology under a research license (research or collaborative
agreement) allowing our partners to confirm the results in their own laboratories
or take the formulation or product concept to the next level of development. Partnering
companies are given the option to enter into a commercial license agreement at any
stage during the validation program to secure access to Arestat™ formulations of their
proprietary molecules for various applications.
It is the usual practice of Arecor to engage potential partners through a technical
presentation and non-confidential discussion of the nature of their molecule and
stability objectives. Following initial contact, should an enquiring partner desire
to proceed further, confidential discussions can be held under a Confidential Disclosure
Agreement (CDA) followed by the preparation of a feasibility study proposal to fit
the requirements of the potential partner outlining the scope of the work, deliverables,
costs and the timeline for consideration.
|
|
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
